Similarity in Pharmacokinetics of Oseltamivir and Oseltamivir Carboxylate in Japanese and Caucasian Subjects
- 1 June 2007
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 47 (6) , 689-696
- https://doi.org/10.1177/0091270007299761
Abstract
The pharmacokinetics of oseltamivir and oseltamivir carboxylate in healthy Japanese (n = 14) and Caucasian (n = 14) males were compared. Subjects in each ethnic group were randomized to twice‐daily oral oseltamivir 75 mg, 150 mg, or placebo for 13 doses. Oseltamivir was well tolerated across doses and ethnic groups. Oseltamivir was rapidly absorbed and hydrolyzed to oseltamivir carboxylate in all subjects. The mean plasma concentration—time profiles for oseltamivir and oseltamivir carboxylate were similar in Japanese and Caucasian subjects. At steady state, there was no evidence of any ethnic difference in the individual AUC0–12 values for oseltamivir or oseltamivir carboxylate. Despite a significant difference in group mean body weight (approximately 20 kg) between the Japanese and Caucasian subjects, there was no evidence that dose‐adjusted AUC0–12 and Cmax for oseltamivir carboxylate were affected by body weight or ethnicity. Day 7 trough concentrations (Cmin) for oseltamivir carboxylate markedly exceeded the IC50 (50% inhibitory concentration) against influenza A and B isolates. In conclusion, the results of this study support the use of the same dose regimens of oseltamivir in both Caucasian and Japanese subjects because of similarity in pharmacokinetics.Keywords
This publication has 30 references indexed in Scilit:
- A multicentre, randomized, controlled trial of oseltamivir in the treatment of influenza in a high-risk Chinese populationCurrent Medical Research and Opinion, 2005
- Functional Consequences of Single Nucleotide Polymorphisms in the Human Organic Anion Transporter hOAT1 (SLC22A6)The Journal of Pharmacology and Experimental Therapeutics, 2005
- Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylateBritish Journal of Clinical Pharmacology, 2005
- Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic PolymorphismsThe Journal of Clinical Pharmacology, 2004
- Determination and analysis of single nucleotide polymorphisms and haplotype structure of the human carboxylesterase 2 genePharmacogenetics, 2004
- Pharmacogenomic assessment of carboxylesterases 1 and 2Genomics, 2004
- Use of Oseltamivir to control influenza complications after bone marrow transplantationBone Marrow Transplantation, 2004
- Safety and Pharmacology of Oseltamivir in Clinical UseDrug Safety, 2003
- Use of the Selective Oral Neuraminidase Inhibitor Oseltamivir to Prevent InfluenzaNew England Journal of Medicine, 1999
- Clinical Pharmacokinetics of the Prodrug Oseltamivir and its Active Metabolite Ro 64-0802Clinical Pharmacokinetics, 1999